Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations
30.3.2026 07:45:00 CEST | Business Wire | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/
Addressing Critical Trade Finance Challenges
The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges.
In many LC transactions, conformity-assessment documents -such as Certificates of Inspection, Certificates of Conformity, or Inspection Reports- are required as part of the documentation package. These documents must be issued prior to export and be verified to ensure LC compliance, which often creates delays and adds operational complexity. The collaboration between Bureau Veritas and Trade Technologies streamlines this process by linking inspection and conformity assessments directly to the trade-finance workflow, enabling faster validation and delivery of the required certificates.
Market Outlook and Growth Potential
The documentary trade sector is forecasted to grow at a 3.1% CAGR through 2029, while receivables finance is projected to expand at 4.2% CAGR during the same period. Documentary trade is expected to remain a core component of the trade finance market well into the 2050s, underscoring the enduring relevance of this collaboration. Current high levels of counterparty and geopolitical uncertainty underscore the value of documentary trade to manage risk in cross-border transactions.
Tangible Benefits for Trade Stakeholders
The collaboration between Trade Technologies and Bureau Veritas promises to deliver meaningful improvements:
- Enhanced Border Efficiency: More streamlined border processes have already contributed to trade cost reductions of up to 5% over the past decade, with ambitious reforms potentially delivering up to 12 percentage points in additional savings.
- Reduced Uncertainty: By combining Trade Technologies' digital trade expertise with Bureau Veritas' deep international trade experience, this collaboration is expected to help exporters, importers, and traders reduce uncertainty and improve visibility.
- Compliance Assurance: The collaboration ensures that applicable standards and/or contractual obligations are met before goods move across borders, strengthening compliance with inspection and conformity requirements.
A Practical Alignment
This strategic collaboration reflects a practical alignment between Trade Technologies, industry-leading digital trade processes and Bureau Veritas’ global network of testing, conformity and inspection experts, enabling better coordination of financial, documentary, and regulatory workflows across global trade corridors.
“Our Certificates of Conformity and Inspection have long served as essential gatekeepers in global supply chains, confirming that goods meet applicable standards before they cross borders”, said Stéphanie Peyrot, Government Services Director for Central Southeast Europe. “Through this collaboration with Trade Technologies, we're now able to integrate these critical documents directly into the trade finance workflow. This means faster processing, greater transparency, and reduced risk for all parties, from exporters and importers to banks and customs authorities. It's about making compliance work for trade, not against it.”
“Bureau Veritas is an important player for vital documents and data to provide certainty of prompt payment under trade finance instruments”, said Kirk Lundburg, CEO of Trade Technologies. “This collaboration simplifies our communication with Bureau Veritas and reduces the time for delivering key data and documents necessary to get our customers paid for their export transactions. We are delighted to partner with Bureau Veritas to reduce risk and complexity for our shared customers.”
***
About Bureau Veritas:
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 82,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
About Trade Technologies:
Trade Technologies is the leading provider of trade finance automation, connectivity, and transaction management services. Established in 1999, the Company has processed almost USD 195 billion in successful trade transactions for thousands of Exporters. Trade Technologies' innovative solutions, including TradeSharp™ and TradeBridge API, automate and digitize the creation, management, and delivery of documents and data between Corporates, Banks and Buyers. With a global presence in 16 offices across Asia, EMEA and North America, the Company offers a unique blend of technology and expert trade services that optimize transaction processing, enhance cash flow, and provide end-to-end visibility. Clients benefit from faster, more reliable payments and reduced costs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260329411683/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release
€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom